This New Drug Combination Doubles the Chance of Keeping Lung Cancer at Bay

The finding could result in annual sales of $4.6 billion by 2023. Adding Roche’s rhhvf immunotherap.....»»

Category: europeSource: fortuneDec 7th, 2017

Roche drug cocktail doubles chance of halting lung cancer

Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts on Thursday labeled unprecedented......»»

Category: topSource: foxnewsDec 7th, 2017

Roche drug cocktail doubles chance of holding lung cancer at bay

Roche's November announcement that its Impower 150 trial had broadly succeeded in first-line lung cancer patients.....»»

Category: topSource: business-standardDec 7th, 2017

Bristol-Myers surges 5.6% on advanced lung cancer trial results, Q4 earnings

Bristol-Myers Squibb Co. shares surged 5.6% in premarket trade on Monday after the company reported positive results for its Opdivo and Yervoy cancer drug combination in a lat.....»»

Category: topSource: marketwatchFeb 5th, 2018

UPDATE: Merck shares jump 7% on news of positive results from lung cancer trial

Merck & Co. Inc. shares jumped almost 7% Tuesday, after the company announced positive results in a late-stage lung cancer trial. The New Jersey-based drug company said the Phase 3 trial of Keytruda in combination with pemetrexed and cisp.....»»

Category: topSource: marketwatchJan 16th, 2018

BioLineRx Begins Trial on BL-8040/ Keytruda Combination

BioLineRx, Ltd. (BLRX) announced the initiation of a phase IIa trial on its lead oncology candidate, BL-8040, in combination with Merck & Co., Inc.???s (MRK) lung cancer drug Keytruda (pembrolizumab). BioLineRx, Ltd. BLRX announced the initiati.....»»

Category: topSource: zacksSep 21st, 2016

AstraZeneca"s immunotherapy drug gets US FDA nod for lung cancer treatment

US FDA granted approval for expanded use of Imfinzi to treat non-small cell lung cancer patients.....»»

Category: topSource: business-standardFeb 17th, 2018

FDA Okays J&J"s Prostate Cancer Drug in First-Line Setting

The FDA lends a nod to the label expansion of Johnson & Johnson's (JNJ) Zytiga in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer. Johnson & Johnson’s JNJ subsidiary, Janssen, ann.....»»

Category: personnelSource: nytFeb 9th, 2018

Merck Strong on Confirmatory Phase III Lung Cancer Study

Merck's (MRK) Keytruda in combination with Eli Lilly's Alimta and carboplatin meet dual primary endpoints in a confirmatory phase III study for the first-line treatment of lung cancer. Merck's MRK shares gained more th.....»»

Category: personnelSource: nytJan 17th, 2018

Merck & Co., Inc. (MRK) Stock Surges on Lung Cancer Drug Success

InvestorPlace - Stock Market News, Stock Advice & .....»»

Category: topSource: investorplaceJan 17th, 2018

Brainstorm Health: Universal Flu Vaccine, Merck Lung Cancer Drug, UnitedHealth Earnings

Brainstorm Health Daily: January 16, 2018 Hello, readers! This is Sy. Google parent Alphabet’s venture arm GV (formerly Google Ventures) is among the companies backing U.K. biotech Vaccitech, which has set out to achieve one.....»»

Category: europeSource: fortuneJan 16th, 2018

Merck leaps past rivals with latest lung cancer drug results

Smoking, which causes many lung cancer cases, has made advanced lung cancer a big market for pharmaceutical companies, and the competition has been fierce......»»

Category: topSource: marketwatchJan 16th, 2018

Merck Wins Big With Late-Stage Lung Cancer Drug Results

Merck saw its shares make a handy gain on Tuesday after it reported that a late-stage trial of Keytruda met its dual primary endpoints......»»

Category: blogSource: 247wallstJan 16th, 2018

UPDATE: Merck shares jump 5% on news of positive results from lung cancer trial

Merck & Co. Inc. shares jumped 5% premarket Tuesday, after the company announced positive results in a late-stage lung cancer trial. The New Jersey-based drug.....»»

Category: topSource: marketwatchJan 16th, 2018

USFDA accepts Panacea Biotec"s ANDA for generic cancer drug

This product is a generic version of Abraxane, which is used for treatment of breast cancer, non-small lung cancer and adenocarcinoma of pancreas, it said......»»

Category: topSource: business-standardNov 30th, 2017

Incyte, AstraZeneca expand collaboration on potential lung cancer therapy

Incyte Corp. is expanding its clinical collaboration with MedImmune, AstraZeneca's global biologics research and development arm. As part of the expanded agreement, the two companies will evaluate the effectiveness and safety of a combination therapy.....»»

Category: topSource: bizjournalsOct 31st, 2017

Merck shares fall deeper into red as European lung-cancer marketing application pulled

Merck & Co. shares fell in the extended session Friday after the drug maker said it was no longer pursuing market approval for a lung cancer drug in Europe. Merck shares declined 2.3% to $56.91 after hours, adding to a 6.1% drop during Friday'.....»»

Category: topSource: marketwatchOct 27th, 2017

Biotech company aims to raise up to $22M in Austin"s next IPO; Cancer-fighting drug in advanced trials

Biotech IPOs have been pretty popular in Austin in recent years. The latest one comes from a company battling non-small cell lung cancer that intends to price its offering at $5 a share......»»

Category: topSource: bizjournalsOct 24th, 2017

Spectrum Pharma Investors Optimistic Over New Lung Cancer Drug

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) shares are trading higher by $7.20 (50 percent) at $21.66 in Wednesday's session. read more.....»»

Category: blogSource: benzingaOct 18th, 2017

Bristol-Myers Gets a Boost

The Checkmate-227 drug trial evaluating non-small cell lung cancer is raising sentiment......»»

Category: topSource: barronsOct 16th, 2017

Lilly"s (LLY) Verzenio Fails in Phase III Lung Cancer Study

Lilly's breast cancer drug, Verzenio, failed to achieve primary e.....»»

Category: personnelSource: nytOct 11th, 2017